Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024.
INVESTORS AND DEVELOPMENT
Ambulero is a pioneer in the use of gene and cell therapy approaches to enhance expression of a key cell adhesion molecule (E-selectin) to treat vascular disease and non-healing wounds. We are pleased to announce our commitment to file an Investigational New Drug (IND) application for our lead product, AMB-301, by late 2024. Once achieved, this significant milestone will bring us closer to testing this gene therapy drug in the clinic.
Investment Background and National Recognition:
-
2023: NIH Approves Second Phase of Funding to Support IND-enabling Work for First-In-Class Ambulero Gene Therapy to Treat Vascular Disease Via The NHLBI Catalzye Program.
-
2023: Ambulero selected to participate in the Endless Frontier Labs (EFL) small business incubator of the NYU/Stern School of Business, New York.
-
2022: Biopitch Semi-Finalist at BioFlorida conference.
-
2022: Ambulero awarded a Cade Prize for its gene therapy approach to treat vascular disease. The award recognizes innovative technology companies within the Southeastern United States.
-
2022: Dr. Velazquez inducted into the American Academy of Medicine for groundbreaking research that forms the basis of Ambulero’s cell and gene therapy platform.
-
2021: FDA grant of Orphan Drug Designation.
-
2019: Initial start-up funding, management, and business support provided by Ventac Holding, LLC.
-
2018: The research work of Dr. Velazquez and Dr. Liu supported by the Wallace H. Coulter Center for Translational Research at the University of Miami.
-
2014: Dr. Omaida Velazquez and Zhao-Jun Liu’s research supported for over a decade by grants from the NIH including funding from the prestigious Vascular Interventions/Innovations and Therapeutic Advances (VITA) program, as well as the Catalyze program of NHLBI.
For more information see the following links :
